Application deadline: 31/12/2018
Vacancies available: 1
A postdoctoral position is available at the Tumor Biomarkers Group at the Vall d´Hebrón Institute of Oncology (VHIO). This group is led by Dr. Josep Villanueva and focuses on the cancer secretome. The cancer secretome contains classical and non-classical secreted proteins that tumor cells use as molecular messengers to communicate with each other and also with their microenvironment. The group aims to characterize the mechanisms adopted by cancer cells to communicate amongst themselves as well as with their microenvironment during tumorigenesis, and exploit these findings to advance biomarker and drug target discovery.
We seek an enthusiastic postdoctoral research scientist with a strong background in cancer biology to develop research on the implications of non-classical secretion in breast cancer biology and therapeutics, using in vitro models as well as patient derived samples.
- Scientific background in cancer cell biology.
- Excellent written and spoken English.
- The successful candidate will have organizational and analytical skills.
- Applicants should be highly motivated and team-oriented.
- The appointed scientist will be expected to design and perform the experiments required to carry out the research project.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net.
Please send applications to firstname.lastname@example.org, stating “Ref. 19/2018” in the subject line of your email.